ClinicalTrials.gg
CompletedNCT04587791Updated Oct 13, 2026

Cannabidiol in Opioid Use Disorder and Chronic Pain

An Early Phase 1 interventional study of 400 mg Cannabidiol and 800 mg Cannabidiol in Chronic Pain and Opioid Use Disorder, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Yale University · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.
Updated Oct 13, 2026Now CompletedNow Active, not recruiting+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing cannabidiol in Chronic Pain — 4 open to participants now, 5 under way, none of them phase 3. Cannabidiol · Chronic Pain.

Enrollment
10th of 11
23 · median 51
Started
2021
with 3 others
Phase 1
5 of 11
1 open now
Registered
4th of 11
by date
Lead sponsor
3 of 11
Yale University

Among the 11 studies testing cannabidiol in Chronic Pain, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 1, and was the 4th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

4 of the 11 studies testing cannabidiol in Chronic Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cannabidiol in Chronic Pain, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone. With a duration of approximately 4 weeks, participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, CBD, will be administered, separated by at least 72 hours to limit carryover effects.

Read the detailed description

Participants with comorbid opioid use disorder (OUD) and non-cancer chronic pain for at least 6 months, currently receiving methadone will be enrolled. Across four test sessions, prior to their daily methadone dose, and thus at trough plasma levels of opioid, participants will receive oral CBD (400 mg, 800 mg, 1200 mg) or placebo. Subsequently, all participants will undergo laboratory testing of opioid-related outcomes.

The order of study medication administration will be counterbalanced order to minimize carryover effects. On the initial screening day and at the end of medication treatment, blood will be drawn to determine serum drug levels. Participants will be thoroughly evaluated by a physician prior to discharge on each experimental session. One week after the last study medication dose, participants will be conducted by phone for a follow-up session.

03

Conditions studied

  • Chronic Pain
  • Opioid Use Disorder

Keywords

  • Methadone
  • Cannabidiol
  • Pain
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, Veterans and non-Veterans, aged between 18 and 70 years old.
  • Diagnosed with OUD and currently enrolled in methadone maintenance treatment.
  • Having chronic pain, uniformly operationalized as grade II (high-intensity) non-cancer pain for ≥ 6 months.
  • Capable of providing in English.
  • Compliant in opioid maintenance treatment and on a stable dose for four weeks or longer.
  • Not meeting criteria for substance use disorders other than OUD or tobacco use disorder within the last 12 months.
  • No current medical problems deemed for participation by principal investigator.
  • For women, not pregnant as determined by pregnancy screening; not breast-feeding; using acceptable methods. Acceptable contraception for females includes oral contraceptives, contraceptive depot injections, contraceptive subdermal implants, intrauterine devices, or surgical contraception methods. Acceptable contraception for males includes condoms or surgical contraception methods.

Exclusion criteria

Exclusion Criteria:

  • Other current major psychiatric disorders deemed clinically unstable by the principal investigator, such as severe depression and/or active suicidal ideation.
  • Having experienced major psychosocial stressors recently (≤ 6 weeks before enrollment), at the discretion of the principal investigator.
  • Methadone dose under 30 mg or over 150 mg/day.
  • Having received inpatient psychiatric treatment recently (≤ 60 days before enrollment).
  • Candidates receiving products containing either THC or CBD will be excluded. All participants will be asked to abstain from cannabinoids. Prior to receiving the study medication on the first test session, participants' cannabinoid use will be assessed using a quantitative point-of-care urine 11-nor-9-carboxy-THC concentration test with a cut-off of ≤ 50 mg/mL. If a participant tests greater than ≤50 mg/mL, they will be asked to abstain for an additional 7 to 14 days. If 14 days after their initial THC concentration test the participant continues to test positive, they will not be allowed to participate in the study.
  • A physician will carefully evaluate participants for use of over-the-counter or prescription psychoactive drugs known to affect pain threshold or pain tolerance (including NSAIDS, serotonin-norepinephrine reuptake inhibitors (SNRIs) (e.g. venlafaxine, duloxetine), gabapentinoids, tricyclic antidepressants (e.g., nortriptyline, amitriptyline), anticonvulsant medications (e.g., topiramate, carbamazepine)). Only participants who are on stable doses (i.e., consistent daily administration of the medication for at least three months at the same dose following the last dose change, either increase or decrease) of these medications, and whose dosing schedules allow participation in the study visits, thus excluding instances of single-dose or temporary dosing of the medication, will be eligible as determined by principal investigator. If possible, the morning dose will be administered after the study visit.
  • Current, regular use of benzodiazepines, other prescription opioids, or inhibitors (e.g., clopidogrel, apixaban, ticagrelor).
  • Current weight of less of 60 kg.
  • Allergy to sesame seed oil, which is an ingredient of the CBD formulation used.
  • Serious medical or neurological illness or treatment for a medical disorder that could interfere with study participation as determined by principal investigator.
  • Participants who have elevation of liver enzymes ( and/or AST) 2x above the normal limit or higher.
  • for exposure to cold temperatures, such as Raynaud's phenomenon and hypertension.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Active comparator
    CBD 400 mg

    CBD 400 mg

    Drug: 400 mg Cannabidiol

  • Active comparator
    CBD 800 mg

    CBD 800mg

    Drug: 800 mg Cannabidiol

  • Active comparator
    CBD 1200 mg

    CBD 1200 mg

    Drug: 1200 mg Cannabidiol

  • Placebo comparator
    Beta carotene oral solution

    Beta carotene oral solution without CBD

    Drug: Beta carotene oral solution without CBD

Interventions

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 400 mg CBD

    Also known as: CBD, Epidiolex

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 800 mg CBD

    Also known as: CBD, Epidiolex

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive 1200 mg CBD

    Also known as: CBD, Epidiolex

  • DrugBeta carotene oral solution without CBD

    Participants will receive beta carotene oral solution without CBD (placebo)

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of CBD measured by the Systematic Assessment for Treatment Emergent Effects (SAFTEE)

    The SAFTEE is a multi-symptom checklist that has been used successfully in the investigators previous studies to assess and monitor any adverse events and possible side effects of study medications. It includes information regarding the severity of any presenting symptoms (0= none, 1= mild, 2= moderate, and 3= severe), as well as the course of action taken by the study staff in response. The SAFTEE is administered before the administration of CBD at baseline, (timepoint -30 minutes) and 4 hours after the administration of CBD (timepoint +240 minutes) during each test session. Data will be presented as the number of participants that reported symptoms on the SAFTEE.

    Time frame: Baseline (30 minutes before the administration of CBD) and +240 minutes after the administration of CBD

  2. Abuse potential of CBD measured by the Drug Effects Questionnaire (DEQ)

    The DEQ will be administered to assess the abuse potential of CBD. The DEQ is a 10-item questionnaire used to assess the subjective effects of psychoactive drugs. Each item is a visual analogue scale (VAS) ranging from 0-100. The questionnaire is used to measure whether a subject feels the drug "feels high", likes or dislikes the effects, and whether they want more of the drug. The primary DEQ outcome will be the Stimulatory Effects subscale, obtained by averaging participants responses to the items: "Feel High"; "Feel Stimulated"; and "Feel the Drug Strength".

    Time frame: Baseline (30 minutes before the administration of CBD), and every 30 minutes after the administration of CBD (up to +240 minutes)

  3. Cognitive effects of CBD measured by the Hopkins Verbal Learning Test (HVLT)

    The HVLT will be used to assess the cognitive effects of CBD. The primary outcomes will be immediate and delayed recall, which index verbal memory. The HVLT consists of a 12-item word list, composed of four words from each of the three semantic categories. The participant is instructed to listen carefully as the examiner reads the word list and attempt to memorize the words. The participants' free recall of the list is recorded. The same procedure is repeated for two more trials (immediate recall). After approximately 15 minutes the participant will be asked to recall as many words from the list as they can without the list being re-read to them (delayed recall).

    Time frame: +210 minutes after the administration of CBD

  4. Cognitive/psychomotor effects of CBD measured by the Continuous Performance Test (CPT)

    The cognitive/psychomotor effects of CBD will be assessed using the Continuous Performance Test (CPT). CPT is a computerized neuropsychological assessment that measures participants sustained and selective attention. For the CPT, the primary outcome will be the throughput score, which indexes attention/working memory accuracy (i.e. percent of correct responses) and speed (i.e. reaction time).

    Time frame: +210 minutes after the administration of CBD

Secondary outcomes

  1. Pain sensitivity measured by Quantitative Sensory Testing (QST) Pain threshold and tolerance

    Pain threshold and tolerance will be assessed using a comprehensive QST battery. This is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience. QST measures are sensitive to the effects of cannabinoids, important biomarkers of chronic pain, and predictors of the pain treatment response. Threshold: the temperature the participant first begins to feel pain (average pain threshold). Tolerance: the temperature when the participant can no longer tolerate the stimuli. The temperature ranges from 37° Celsius to 50° Celsius. A lower temperature represents a lower pain threshold/tolerance and a higher temperature represents a higher pain threshold/tolerance.

    Time frame: Baseline (30 minutes before the administration of CBD), +120 minutes and +240 minutes after the administration of CBD.

  2. Pain sensitivity measured by change in Quantitative Sensory Testing (QST) Conditioned Pain Modulation (CPM)

    CPM indexes top-down pain inhibition, by leveraging the "pain inhibits pain phenomena". In CPM, a test stimulus is rated on a -100 to +100 Numeric Rating Scale (NRS) for pain both alone and during a concurrent conditioning stimulus applied elsewhere on the body. The CPM Score is the difference between these two ratings. CPM score is a Difference (Delta): Pain rating (test stimulus alone) - Pain rating (test stimulus with conditioning stimulus) Interpretation: Higher (more positive) values indicate greater pain inhibition.

    Time frame: Baseline (30 minutes before the administration of CBD), +120 minutes and +240 minutes after the administration of CBD.

  3. Pain sensitivity measured by Quantitative Sensory Testing (QST) Temporal Summation of Pain (TSP)

    TSP involves the repeated administration of noxious stimuli, indexing bottom-up pain facilitation. Therefore, TSP measures the increase in pain perception with repeated noxious stimuli, calculated as the area under the curve (AUC) of pain ratings over time during repeated stimulation. Higher TSP scores indicate worse outcomes (greater pain facilitation/central sensitization), while lower TSP scores indicate better outcomes (less pain facilitation/central sensitization). The TSP AUC values represent the cumulative pain experience during repeated stimulation (VAS units\*seconds), where larger values reflect greater temporal summation of pain, which is associated with central nervous system sensitization and chronic pain conditions.

    Time frame: Baseline (30 minutes before the administration of CBD), +120 minutes and +240 minutes after the administration of CBD.

  4. Response to Quantitative Sensory Testing (QST) battery measured by Pain Visual Analog Scale (VAS)

    The pain VAS will be used by participants as a secondary rating scale for pain severity pain testing. This scale ranges from 0 to 100 and contains of a horizontal line, anchored by verbal descriptors of "no pain" and "pain as bad as it could be". Participants will place a vertical line at the point that best indicates their present pain.

    Time frame: Baseline (30 minutes before the administration of CBD), +120 minutes and +240 minutes after the administration of CBD.

  5. Pain Catastrophizing measured by the Pain Catastrophizing Scale (PCS)

    The PCS is a 13-item self-report scale designed to measure negative thoughts and feelings associated with pain. Each item is rated on a 5-point scale: 0 (Not at all) to 4 (all the time). Total scores range from 0 to 52, with higher scores indicating greater catastrophizing. The PCS contains three subscales: magnification (scores ranging from 0-12), rumination (scores ranging from 0-16), and helplessness (scores ranging from 0-24).

    Time frame: Baseline (30 minutes before the administration of CBD)

  6. Opioid craving measured by change in the Heroin Craving Questionnaire - Short Form 14 (HCQ-SF-14)

    The HCQ-SF-14 consists of 14 statements about the respondent's feelings and thoughts about using heroin as he or she is completing the questionnaire (i.e., right now). Each of the 14 items is scored on a scale from 1 (Strongly Disagree) to 7 (Strongly Agree). The HCQ-SF-14 score is obtained by adding the scores of all 14 statements and dividing the total by 14. Higher scores on the HCQ-SF-14 indicate a stronger craving for heroin. The HCQ-14 was administered before (+150 minutes) and after (+155 minutes) participants watched a cue-induced craving video. The difference of the two HCQ-14 scores (post - pre) will be used to index cue-elicited craving.

    Time frame: Average difference of scores from before cue-induced craving video (+150 minutes) and after cue-induced craving video (+155 minutes)

  7. Opioid craving measured by the Subjective Opiate Withdrawal Scale (SOWS)

    The SOWS is a 16-item, participant-administered questionnaire designed to rate the intensity of opioid withdrawal symptoms. It assesses symptoms on a 0-4 scale ("not at all" to "extremely"), with total scores of 1-10 indicating mild, 11-20 moderate, and 21-30 severe withdrawal.

    Time frame: Baseline (30 minutes before the administration of CBD), +30 minutes, +90 minutes, +150 minutes, +210 minutes, and +240 minutes after the administration of CBD

  8. Negative affect measured by the Positive and Negative Affect Schedule (PANAS)

    The PANAS is a 20-item self-report questionnaire listing adjectives relating to Positive Affect (PA) (e.g., excited, inspired) and Negative Affect (NA) (e.g., distressed, afraid). Items are rated on a Likert scale ranging from 1 "Very slightly or not at all" to 5 "extremely". The PANAS yields separate PA and NA scores, each ranging from 10 to 50. Higher PA scores indicate more positive feelings, while higher NA scores indicate more negative feelings. These scores are used to track emotional states over time. The PANAS will be used to measure the effects of CBD on mood.

    Time frame: Baseline (30 minutes before the administration of CBD), and every 30 minutes after the administration of CBD (up to +240 minutes)

Other outcomes

  1. Influence of sex

    The investigator will explore if sex moderates the relationships hypothesized in the primary and secondary objectives.

    Time frame: Up to 6 hours

07

Study locations

1 site
  • Department of Veterans Affairs Hospital
    West Haven, Connecticut 06516, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2025, 39 months.

Of 60 phase 1 interventional studies under Chronic Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 56. This study's 39 months is above that.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2025, last on Oct 13, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2025, last on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2020
First posted
Oct 14, 2020
StartActual
Dec 8, 2021
Primary completionActual
Mar 19, 2025was Aug 2026
CompletionActual
Mar 19, 2025was Aug 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 5, 2026 · changed Oct 13, 2026
Primary completion
Aug 31, 2026→Mar 19, 2025 (actual)
moved 2 times, Oct 5, 2026 – Oct 13, 2026
Study completion
Aug 31, 2026→Mar 19, 2025 (actual)
moved 2 times, Oct 5, 2026 – Oct 13, 2026
Enrollment
34 (estimated)→23 (actual)
Oct 13, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • EditedDiagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment.
Exclusion criteria
  • RemovedBuprenorphine dose over 24 mg per day.
Oct 13, 2026
Show all 2 updates
  1. Oct 13, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2027→Mar 19, 2025 (now actual)
    Study completion Dec 31, 2027→Mar 19, 2025 (now actual)
    Enrollment 34 (estimated)→23 (actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment.
    Exclusion criteria
    • RemovedBuprenorphine dose over 24 mg per day.
    + 4 other changes: verification date, description, conditions and data sharing statement
  2. Oct 5, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 31, 2026→Dec 31, 2027
    Study completion Aug 31, 2026→Dec 31, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04587791
Lead sponsor
Yale University
Collaborators
VA Connecticut Healthcare System, National Institute on Drug Abuse (NIDA)
Responsible party
Joao De Aquino (Assistant Professor of Psychiatry, Yale University) — Principal investigator
First posted
Oct 14, 2020
Start date
Dec 8, 2021
Primary completion
Mar 19, 2025
Completion
Mar 19, 2025
Last update
Oct 13, 2026

Study contacts

Joao De Aquino, M.D.
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion